United Therapeutics Corporation financials
Key figures from United Therapeutics Corporation's filings with the U.S. Securities and Exchange Commission: the latest quarter against a year earlier, and the trend across recent quarters and fiscal years.
Latest quarter vs a year earlier
| Metric | Jun 2026 | Jun 2025 | Change |
|---|---|---|---|
| Revenue | $783M | $799M | -1.9% |
| Net income | $333M | $310M | +7.6% |
| Free cash flow | $206M | $130M | +58.8% |
| Gross margin | 87.3% | 89.0% | -1.7 pts |
| Operating margin | 42.2% | 45.6% | -3.4 pts |
| Net margin | 42.5% | 38.8% | +3.8 pts |
Quarterly trend
Fiscal years
| Fiscal year | Revenue | Net income | Net margin | Free cash flow | EPS (diluted) |
|---|---|---|---|---|---|
| FY Dec 2025 | $3.2B | $1.3B | 41.9% | $1.0B | $27.86 |
| FY Dec 2024 | $2.9B | $1.2B | 41.5% | $1.1B | $24.64 |
| FY Dec 2023 | $2.3B | $985M | 42.3% | $748M | $19.81 |
| FY Dec 2022 | $1.9B | $727M | 37.6% | $664M | $15.00 |
| FY Dec 2021 | $1.7B | $476M | 28.2% | $477M | $10.06 |
* Fiscal fourth quarter computed from the annual filing minus the three reported quarters. All figures from company filings with the SEC.